MYCN and neuroblastoma: Recent studies have shown that MNA is not associated with poorer outcome among the overall cohort of patients with HR-NB, but the presence of genomic amplifications other than MYCN might constitute a poor outcome biomarker.43 We now show in this large ALK analysis cohort that the presence of ALKa or clonal ALKm resulted in significantly worse outcome.